Business
Hoth Therapeutics Announces Positive Preclinical End Point Results of HT-ALZ Treatment for Alzheimer's Disease
HT-ALZ Showed Improvement on Several Tests of Cognitive FunctionHT-ALZ Showed Positive Benefits with Reductions in AnxietyCompleted Dose Response Study Leads
About this update from Hoth Therapeutics, Inc.
[{"type":"text","content":"HT-ALZ Showed Improvement on Several Tests of Cognitive FunctionHT-ALZ Showed Positive Benefits with Reductions in AnxietyCompleted Dose Response Study Leads Hoth to Begin Formulation Development\nNEW YORK, Aug. 9, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that HT-ALZ, a therapeutic in development for the treatment of Alzheimer's Disease (\"AD\"), achieved positive preclinical end points in a study conducted at Washington University, St. Louis.\nSubjects treated with HT-ALZ show improvement on several tests of cognitive function, including spatial learning and memory, sensorimotor gating, and contextual associative memory. HT-ALZ showed positive benefits with reducing anxiety- like behavior in mice.\n\n\nAD is a neurodegenerative disease that is characterized by aggregates of amyloid β (Aβ) plaques and neurofibrillary tangles of Tau protein in the brain, which contribute to the clinical symptoms of the disease, such as dementia. Previously Hoth reported study results focused on investigating the effect of orally administered HT-ALZ to reduce the concentration of Aβ in the brain interstitial fluid, using an established Alzheimer's Disease mouse model (aged APP/PS1+/- mice). The initial data from those studies showed a significant decrease in Aβ in both male and female APP/PS1+/- mice after acute treatment with HT-ALZ, compared to placebo-treated animals and baseline Aβ levels.\nAbout Hoth Therapeutics, Inc. Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to develop innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. To learn more, please visit https://ir.hoththerapeutics.com/ .\nForward-Looking Statement This press release includes forward-looking statements based upon Hoth's current expectations which may constitute forward-looking statements for the purposes of the safe harbor provisio...